Pharmaceutical company Alchemab Therapeutics (Alchemab) announced on Thursday that it has named Jane Osbourn, OBE, FMEDSCI, PhD as its new chief executive officer (CEO) and member of the board.

Osbourn is to succeed Young Kwon, PhD. She has over 30 years of biopharmaceutical industry experience and has worked as vice president of R&D at MedImmune. Obsbourn cofounded Alchemab in 2019 and serves as a Venture Partner at SV Health Investors. She has worked as a director of Babraham Bioscience Technologies, Cambridge Enterprise, the Crick Translational Advisory Group, and was chair of the board of directors of the UK BioIndustry Association.

Alchemab chair and managing partner at SV Health Investors, Kate Bingham, said, 'As the founding investors, we have been huge supporters of the highly innovative approach at Alchemab since its inception. We have been thrilled with Jane's leadership to date as CSO and look forward to backing her as CEO. It has been fantastic to support Alchemab's journey from a start-up occupying our incubator space, to a high growth company. Jane's knowledge of Alchemab and the wider industry is unparalleled, and her significant organisational and scientific expertise will play a critical role in driving the Company through its next stage of growth. We thank Young for his contribution to the success of Alchemab to date, and wish him all the best for his next role.'